# SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation

> **NCT04486937** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Jiangxi Qingfeng Pharmaceutical Co. Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** S410914 tablet

## Key facts

- **NCT ID:** NCT04486937
- **Lead sponsor:** Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-30
- **Primary completion:** 2021-12-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2020-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04486937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04486937, "SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04486937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*